In a study published in Nature Medicine, researchers report an artificial intelligence (AI)-based digital pathology tool for scoring metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis (NASH)) histology. MASH clinical trial enrollment and endpoint assessment are based on histological criteria. The tool, which is termed AIM-MASH, produced predictions for steatosis grade and fibrosis stage that were comparable to consensus MASH Clinical Research Network grading and staging. The aim of the tool is to reduce variability in interpretation for trial outcomes, improve sensitivity of scoring systems and assist pathologists in histological review of clinical trials for MASH.